Today UNICEF announced it would purchase a supply of the world’s second malaria vaccine, R21/Matrix-M, in a deal to inoculate children in vulnerable regions. The 4-year deal is contingent on pre-qualification of the product from the World Health Organization (WHO).
“It is heartbreaking and unacceptable that almost half a million children die of malaria every year. This agreement is a critical step towards protecting more children from this deadly disease,” said Director of UNICEF Supply Division Leila Pakkala, MD, in a press release on the agreement.
The WHO estimates malaria kills one child under age 5 every minute.
R21/Matrix-M follows RTS,S, the first approved malaria vaccine anticipated to start being used later this year. They are the first two vaccines to target a parasitic disease, and are the result of 35 years of research and development.
UNICEF is the world’s largest vaccine purchaser, buying more than 2 billion doses of vaccines annually for routine childhood immunizations in 100 countries around the world.